首頁 > 市場調查報告書 > 製藥

麻醉

市場調查報告書

商品編碼

1899919

全身麻醉劑市場規模、佔有率和成長分析（按藥物類型、給藥途徑、最終用途、應用領域和地區分類）－2026-2033年產業預測

General Anesthesia Drugs Market Size, Share, and Growth Analysis, By Drug Type (Propofol, Sevoflurane), By Route of Administration (Intravenous, Inhaled), By End-Use, By Application, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月19日 | 出版商:

SkyQuest | 英文 260 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，全身麻醉劑市場規模將達到 57.9 億美元，到 2025 年將達到 59.9 億美元，到 2033 年將達到 78.9 億美元，預測期（2026-2033 年）的複合年成長率為 3.5%。

由於外科手術數量的增加和創新麻醉劑的問世，全身麻醉劑市場正經歷顯著成長。全身麻醉主要透過靜脈注射給藥，透過抑制自主神經系統反應來誘導意識喪失和緩解疼痛。這項技術尤其廣泛應用於心血管手術和慢性腎臟病治療。美容和重組手術的興起進一步推動了市場需求，全球每年進行數百萬例大型手術。新型局部麻醉劑和鎮靜劑等新產品核可，正成為該產業公司盈利的收入來源。因此，外科手術數量的增加和創新藥物的研發預計將在未來幾年推動市場擴張。

全身麻醉劑市場成長要素

癌症患者數量的不斷成長是推動全身麻醉劑市場需求的主要因素。隨著數百萬癌症倖存者的出現，並且預計這一群體還將持續成長，對手術干預的需求也在增加，因為在癌症早期發現時，手術往往是最有效的治療手段。肺癌、乳癌和大腸癌等常見癌症都需要手術治療，而全身麻醉通常是有效控制疼痛和緩解焦慮的必要手段。隨著越來越多的患者接受各種腫瘤的手術治療，全身麻醉的依賴將進一步增強，醫療保健系統為滿足這些日益成長的手術需求，也將推動市場向前發展。

全身麻醉劑市場的限制

全球全身麻醉劑市場的主要限制因素之一是麻醉劑相關副作用發生率的不斷上升，這引發了醫護人員和病患的安全疑慮。諸如呼吸系統併發症、過敏反應和術後認知障礙等不良反應的報告可能導致人們不願意使用這些藥物。監管機構也正在對某些麻醉劑的使用施加更嚴格的指導方針，這使得核准和市場准入變得更加複雜。此外，隨著臨床醫生尋求更安全、創傷更小的麻醉方案，人們對區域麻醉和鎮靜等替代麻醉技術的興趣日益濃厚，這可能會進一步限制市場的成長潛力。

全身麻醉劑市場趨勢

全身麻醉劑市場正經歷顯著成長，這主要得益於旨在改善臨床療效和促進患者康復的強勁研發活動。評估各種麻醉劑（包括吸入和靜脈注射麻醉藥，例如Propofol）療效的創新研究激增，從而改善了患者的體驗。這種對最佳化麻醉通訊協定日益重視的趨勢反映了個人化醫療的廣泛發展，相關人員都渴望改進現有藥物並開發新的製劑。此外，技術進步以及對患者安全和舒適度的日益重視也進一步推動了市場擴張，為麻醉劑的研發和應用創造了充滿活力的環境。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2021-2023年營收年比比較

主要企業簡介

AstraZeneca（UK）
Baxter International Inc.（USA）
Fresenius SE & Co. KGaA（Germany）
AbbVie Inc.（USA）
B. Braun Melsungen AG（Germany）
Hikma Pharmaceuticals PLC（UK）
Teva Pharmaceutical Industries Ltd.（Israel）
Pfizer Inc.（USA）
Novartis AG（Switzerland）
Mylan NV（USA）
Piramal Enterprises Limited（India）
Eisai Co., Ltd.（Japan）
F. Hoffmann-La Roche Ltd.（Switzerland）
GlaxoSmithKline plc（UK）
Johnson & Johnson（USA）
Merck & Co., Inc.（USA）
Sanofi SA（France）
Sun Pharmaceutical Industries Ltd.（India）
Takeda Pharmaceutical Company Limited（Japan）
Abbott Laboratories（USA）

結論與建議

簡介目錄

Product Code: SQSG30B2035

General Anesthesia Drugs Market size was valued at USD 5.79 Billion in 2024 and is poised to grow from USD 5.99 Billion in 2025 to USD 7.89 Billion by 2033, growing at a CAGR of 3.5% during the forecast period (2026-2033).

The general anesthesia drugs market is experiencing significant growth due to the increasing number of surgical procedures and the introduction of innovative anesthetic medications. General anesthesia induces unconsciousness, pain relief, and suppresses autonomic nervous system responses, primarily through intravenous (IV) techniques, which are especially prevalent in cardiovascular and chronic renal procedures. The rise in cosmetic and reconstructive surgeries further amplifies demand, with millions of major surgeries conducted globally each year. New product approvals, like novel local anesthetics and procedural sedation agents, are emerging as lucrative revenue streams for companies in this sector. Thus, the synergy of rising surgical volumes and innovative drug development is expected to propel market expansion in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the General Anesthesia Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

General Anesthesia Drugs Market Segments Analysis

Global General Anesthesia Drugs Market is segmented by drug type, Route of Administration, end-use, application and region. Based on drug type, the market is segmented into propofol, sevoflurane, desflurane, ketamine, thiopental, etomidate and others. Based on route of administration, the market is segmented into intravenous and inhaled. Based on end-use, the market is segmented into hospitals, ambulatory surgical centers, clinics and others. Based on application, the market is segmented into cardiovascular surgery, orthopedic surgery, neurosurgery, general surgery, cosmetic surgery and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the General Anesthesia Drugs Market

The growing prevalence of cancer is significantly driving demand in the General Anesthesia Drugs market. With millions of cancer survivors and an anticipated increase in this population, the need for surgical interventions rises, as these procedures often represent the most effective means of treatment when cancer is detected early. Common cancers like lung, breast, and colorectal cancers necessitate surgeries, which typically require general anesthesia for effective management of pain and anxiety. As more patients undergo operations to address various types of tumors, the reliance on general anesthesia will likely intensify, propelling the market forward as healthcare systems adapt to meet these increasing surgical needs.

Restraints in the General Anesthesia Drugs Market

One significant market restraint in the global general anesthesia drugs market is the increasing prevalence of adverse effects associated with anesthetic agents, which raises safety concerns among healthcare providers and patients alike. Reports of side effects such as respiratory complications, allergic reactions, and postoperative cognitive dysfunction can lead to reluctance in the adoption of these drugs. Regulatory bodies are also imposing stricter guidelines on the usage of certain anesthetics, complicating their approval and market entry. Furthermore, the growing interest in alternative anesthesia methods, including regional anesthesia and sedation, may further limit the market's growth potential as clinicians seek safer and less invasive options.

Market Trends of the General Anesthesia Drugs Market

The general anesthesia drugs market is experiencing significant growth driven by robust research and development efforts aimed at enhancing clinical outcomes and patient recovery. A surge in innovative studies assesses the efficacy of various anesthetics, such as inhaled agents and intravenous options like propofol, leading to improved patient experiences. This heightened focus on optimizing anesthetic protocols reflects a broader trend towards personalized medicine, with stakeholders keen on adapting existing drugs and developing new formulations. Additionally, technological advancements and a growing emphasis on patient safety and comfort further bolster market expansion, establishing a dynamic landscape for anesthesia drug development and application.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Patent Analysis

Global General Anesthesia Drugs Market Size by Drug Type & CAGR (2026-2033)

Market Overview
Propofol
Sevoflurane
Desflurane
Ketamine
Thiopental
Etomidate
Others

Global General Anesthesia Drugs Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Intravenous
- Bolus Injection
- Continuous Infusion
Inhaled
- Volatile Liquids
- Gases

Global General Anesthesia Drugs Market Size by End-Use & CAGR (2026-2033)

Market Overview
Hospitals
Ambulatory Surgical Centers
Clinics
Others

Global General Anesthesia Drugs Market Size by Application & CAGR (2026-2033)

Market Overview
Cardiovascular Surgery
Orthopedic Surgery
Neurosurgery
General Surgery
Cosmetic Surgery
Others

Global General Anesthesia Drugs Market Size & CAGR (2026-2033)

North America (Drug Type, Route of Administration, End-Use, Application)
- US
- Canada
Europe (Drug Type, Route of Administration, End-Use, Application)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Type, Route of Administration, End-Use, Application)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Type, Route of Administration, End-Use, Application)
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Type, Route of Administration, End-Use, Application)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

AstraZeneca (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Baxter International Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fresenius SE & Co. KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
B. Braun Melsungen AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hikma Pharmaceuticals PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Piramal Enterprises Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eisai Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments